Contemporary Management of 1-4 Brain Metastases

about

Contemporary Management of 1-4 Brain Metastases

Item

http://www.wikidata.org/entity/Q57492449

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Contemporary Management of 1-4 Brain Metastases

@en

Contemporary Management of 1-4 Brain Metastases

@nl

type

Item

label

Contemporary Management of 1-4 Brain Metastases

@en

Contemporary Management of 1-4 Brain Metastases

@nl

prefLabel

Contemporary Management of 1-4 Brain Metastases

@en

Contemporary Management of 1-4 Brain Metastases

@nl

P1476

Contemporary Management of 1-4 Brain Metastases

@en

P2093

Erin S Murphy

http://www.w3.org/2001/XMLSchema#string

Jennifer S Yu

http://www.w3.org/2001/XMLSchema#string

John H Suh

http://www.w3.org/2001/XMLSchema#string

Samuel T Chao

http://www.w3.org/2001/XMLSchema#string

Sarah M C Sittenfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases

Management of brain metastases.

Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis.

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Stereotactic Radiosurgery: Treatment of Brain Metastasis Without Interruption of Systemic Therapy.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA).

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

P304

385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00385

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30319962

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6165904

http://www.w3.org/2001/XMLSchema#string